SITC Archive Library

Back to Library

SITC 29th Annual Meeting (2014): Late-Breaking Abstract Session II 

02-21-2017 10:09

SITC 29th Annual Meeting: Late-Breaking Abstracts Session II 
November 7-9, 2014
Gaylord National Hotel & Convention Center National Harbor, MD

SITC 29th Annual Meeting Organizers 
Arthur A. Hurwitz, PhD - National Cancer Institute
Kim A. Margolin, MD - Stanford University
Daniel E. Speiser, MD - Ludwig Center for Cancer Research of the University of Lausanne
Walter J. Urba, MD, PhD - Earle A. Chiles Research Institute, Providence Cancer Center

About the SITC 29th Annual Meeting
The SITC 29th Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations, and ample opportunities for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.

#ClinicalTrials #CervicalCancer #PresentationSlides #Abstracts #AnnualMeeting #SITC #AdoptiveCellTherapy #CombinationTherapy #ImmuneCheckpointInhibitors
 #Vaccines #Clinician #Industry #Oncologist #Researcher  #2014​

Statistics
0 Favorited
15 Views
2 Files
0 Shares
37 Downloads
​
Attachment(s)
Download All
pdf file
Results of a Randomized, Double-Blind, Placebo-Controlle...   2.17 MB   1 version
Uploaded - 02-21-2017
Meeting: SITC 29th Annual Meeting; Session: Late-Breaking Abstract Session; Presentation: DNA Vaccine VGX-3100 with Electroporation Induces Regression of Cervical Intraepithelial Neoplasia 2/3 and Clears HPV Infection with Robust T Cell Responses: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial; Presenter: Laurent M. Humeau, PhD – Inovio Pharmaceuticals; Date: November 8, 2014
 
Download
pdf file
OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T C...   2.89 MB   1 version
Uploaded - 02-21-2017
Meeting: SITC 29th Annual Meeting; Session: Late-Breaking Abstract Session; Presentation: OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells with a Unique T Cell Receptor Repertoire and Synergizes with PDL1 Blockade to Promote Tumor Regression; Presenter: Amy E. Moran, PhD – Earle A. Chiles Cancer Research Institute, Providence Cancer Center; Date: November 8, 2014
 
Download